Alimera completes $40 million convertible preferred stock sale Alimera Sciences.

Alimera completes $40 million convertible preferred stock sale Alimera Sciences, Inc http://silagrahelp.com/contact-us . , a biopharmaceutical firm that specializes in the research, development and commercialization of prescription ophthalmic pharmaceuticals, today announced that it has completed the sale of $40 million of Series A Convertible Desired Stock and warrants to get Series A Preferred to a group of institutional investors, including both existing and new investors, in a private placement. We believe the closing of the financing combined with our current cash position will enable us to proceed with the immediate commercialization of ILUVIEN in Germany, the uk and France, without having to raise any extra funds for this purpose, stated Dan Myers, Alimera’s President and CEO.

We continue to advance this important plan.’ Pediatric Study Alexion has commenced a Phase 2, open-label, single-arm, multi-center research of eculizumab in pediatric patients with aHUS in the usa, European Canada and Union. Information regarding the trial is posted to Identifier Number NCT01193348. Physicians and family members who want in participating in this scientific trial can learn more by contacting Alexion by e-mail at , or at the Alexion website in and clicking on the clinical trials hyperlink.. Alexion’s Soliris Phase 2 clinical study for aHUS meets main, secondary endpoints Alexion Pharmaceuticals, Inc. The brand new data are consistent with an earlier interim analysis within the abstract of today’s display and released online by ASN on October 20, 2010. Soliris is a first-in-course terminal complement inhibitor developed and discovered by Alexion.